Chapter 1: Process Model Evolution Launch Landmark on 1st June in London Attendees were warmly welcomed on June 1st and 2nd at the elegant Landmark Hotel in London. The event drew participants from afar as Japan (Asahi Kasei and Chugai Pharmaceutical) and Texas, USA (BDO). The gathering was prestigious, warm,

Come and see an automated biologics processing unit in operation at a one-day Symposium “Integrated Process Strategies For Regional Biopharmaceutical Supply” on March 28, 2023, Sedgefield, UK. Looking back down the race circuit, the horses don’t seem to be moving quickly – until they come thundering past you, covering twice

The historical development of antibody drug conjugates is a well told yarn, where self-immolating reactions are scribbled on ESACT conference paper with PEGS free-issue pens. These multidisciplinary scientists and the molecules they make are writing a new storyline now. Increased activity With six approvals of new ADCs in the last

With Regeneron’s high profile, single-person, single-site, clinical trial proving successful (along with much supporting other clinical data!), will neutralising antibodies surf the second wave? Our COVID-related blogs focus on capacity and cost of making the treatments and understanding opportunities or bottlenecks in large scale provision and new innovations. In this

Are you interested in optimising performance of your upstream biologics manufacturing? Cell retention/media perfusion devices increase the viable cell density of bioreactors and can be used to reduce the number or volume of seeding stages of the production bioreactor (1,2,3). Additionally, the production cycle can be initiated earlier, with a

A Case Study based on the Covid-19 vaccine being developed by the Jenner Institute, Oxford University. An affordable, global vaccine for Covid-19 is still seen as the best chance of protecting vulnerable people and populations at the same time as getting everyone back to normal activity. There are now 79

The biopharmaceutical industry is investigating various biologics as treatments for COVID-19. This blog looks at the scale of global manufacturing that may be required and the associated cost of goods of these drug products for COVID-19. Vaccine manufacturing will be discussed in a separate blog. What manufacturing capacity might be

Biopharmaceutical manufacturing capacity, efficiency, flexibility and economics are all important outputs for organisations to optimize and continuously review. BioSolve Process is the biopharmaceutical industry’s most powerful software for bioprocess analysis. Due to the complexity of therapeutic manufacturing there are many variables contributing to the overall manufacturing performance. BioSolve Process has

As cell therapy processes mature and advance further beyond clinical trials, the shift to the manufacture and supply of affordable therapies will become more important. These therapies are expensive. High cost of goods (COGs) can be a cause of commercial failure with cell therapies, so manufacturing processes and logistics need

As we develop new processes and evaluate new technologies it is important to consider sustainability and the environmental impact and how this can be improved. It is an area that we have been actively considering since the early days of BioSolve Process; when the focus of the industry was on

World-class bioprocess modelling software developer unveils new customisable features for users. LONDON, 11 December 2019 – Biopharm Services, the bioprocess analysis software developer, today announced the release of the latest version of its flagship process analysis and economic modelling tool, BioSolve Process. BioSolve Process 8 is the latest version of

The BioSolve User forum was held in the historic town of Leiden; we welcomed over 20 attendees. We met together for a in-depth review of new features, and to learn from and interact with other users in the expanding community. A major theme of the day was the role of

This is the exact question we asked an audience in a session led by our Sales & Marketing Director Dr Yuki Abe, alongside GE Healthcare’s Jonathan Royce at our User Group Forum back in April 2018. By using the power of real time polling, we asked 36 audience members nine

Held in April at le Meriden Cambridge MA, Now in its 10th year the forum ably illustrated the applicability of BioSolve Process to a wide range of challenges we face in bioprocessing. It was pleasing to see representatives from the Biopharm supply chain; from academics, consultant engineers, suppliers and manufacturers.

This week we announced that we have supported the BioPhorum Operations Group in the development of the first edition of The Technology Roadmap for the Biopharmaceutical Manufacturing Industry. So why did we get involved? As we all know, current trends in the biopharmaceutical industry, including continued market growth, the arrival

Biopharm Services recently conducted its annual survey of BioSolve users. The survey is a great opportunity for all users to provide valuable insight and thoughts that contribute directly to the future development direction of the BioSolve products. Today we’d like to share some highlights from our user survey. Majority using

As the leaves started to fall from the trees in the iconic city of London, Biopharm Services hosted the 2016 BioSolve User Group Forum. BioSolve users from across the world came together to gain insight into a range of topics focused around cost estimation and technology evaluation in the bioprocess industry.

Following the success of the first BioSolve User Group forum last year, we are delighted to announce the second forum, set to take place on September 22nd and 23rd at the Hilton London Paddington. Following last year’s event in the US, we hope that many of our European users will be

We recently approached a number of expert individuals that we felt could support Biopharm Services by joining our new steering committee. The aim of the committee is to help support us shape our future direction with their knowledge and vision of the sector. We are delighted to announce that the

We recently conducted our annual User Survey – many thanks to all our users who participated. We use the survey to gather valuable insight into our users’ experience with BioSolve, and it often leads to product improvements and enhancements based on user feedback. Overall, responses to the survey were overwhelmingly

It was great to see so many faces at the first Biopharm User Group meeting. More than 30 attendees joined us in Phildelphia on 17th & 18th September for what was a lively event, based on the real experiences of our users. Here are a few talks that were given

Ever since BioSolve Process was first introduced, our software has not only been helping companies improve the way they do business, but it has also been used to help generate academic research in process development by many of the leading innovators in the field. The software is commonly used to

In response to a growing number of requests from users, Biopharm is delighted to announce the creation of a BioSolve User Group meeting series. The inaugural meeting will happen this September in Philadelphia and we hope that many of our users will be able to join us there for what

Last month, Biopharm’s managing director, Andrew Sinclair, and Dr. Yuki Abe headed to Dublin, Ireland, for the Continuous Manufacturing in Biopharmaceuticals conference hosted by Informa Life Sciences. In conjunction with Jean-Francois Hamel from MIT, the Biopharm team led a pre-conference workshop entitled Implementing a Continuous Manufacturing Process: Key Considerations for

What’s happening in downstream processing? Welcome to the latest instalment of our continuous processing blog series. In Part 2 we considered the overall cost picture of the economics of continuous processing and touched upon the impact of perfusion versus fed batch – a theme we will pick up again later

Last month, Biopharm joined hundreds of exhibitors and thousands of visitors in attending Interphex Japan. The Tokyo-based tradeshow and conference covers the whole process of pharmaceuticals R&D and manufacturing. On the first day, Mark Bamforth, CEO of Gallus Pharmaceuticals, gave a keynote presentation on “The Executive’s Dilemma: the Make vs

Some biopharma companies have been running perfusion bioreactors in a continuous mode for several decades. The choice of whether to use continuous or not was dictated by the product, and little has been published on the economics of continuous perfusion processes. In today’s blog we take a look the economics

Over the next couple of blogs, we’d like to take a closer look at continuous processing, including the challenges associated with it, focusing on the cost drivers for perfusion versus fed batch, and the potential for continuous downstream processing. Continuous processing has increasingly been seen as having the potential to

In conjunction with today’s launch of BioSolve Process 5, we have developed a whitepaper that demonstrates the significant savings that can be achieved by biopharma innovators in monoclonal antibody manufacture. The study used BioSolve Process to evaluate three different development scenarios: Current stainless steel technology Modelling in BioSolve Process shows